Abstract The coronavirus disease 2019 (COVID-19) pandemic has led to a concerning
resurgence of mucormycosis. More than 47,000 cases of mucormycosis were reported in …

Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening
infectious complications following allogeneic hematopoietic stem cell transplantation …

Human cytomegalovirus (HCMV) reactivation is a major infectious cause of morbidity and
mortality after allogeneic hematopoietic stem cell transplantation (HSCT). HCMV is a …

Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of
cytomegalovirus (CMV) reactivation and disease, which results in increased morbidity and …

Background Cytomegalovirus (CMV) infection remains an important cause of morbidity and
mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell …

Abstract The Practice Guidelines Committee of the American Society of Transplantation and
Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID …

Letermovir potently inhibits the cytomegalovirus (CMV)-terminase complex. Letermovir
primary prophylaxis given for the first 3 months after allogeneic hematopoietic cell …

Morbidity and mortality after allogeneic hematopoietic cell transplantation (alloHCT) are still
essentially affected by reactivation of cytomegalovirus (CMV). We evaluated 80 seropositive …

CMV infection is associated with increased risk of IFD in posttransplant recipients because
of a number of overlapping and virus-specific risk factors. Better understanding of how CMV …

Cytomegalovirus (CMV) represents one of the most common infectious complications after
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, a common …